A study by the University of California, Los Angeles, found a new way to predict which “stable heart failure” patients have a higher risk of dying within one to three years. The study found that patients with higher levels of neuropeptide Y, a molecule released by the nervous system, were ten times more likely to die within one to three years than those with lower levels of neuropeptide Y.
On average, about half of heart failure patients die within five years of diagnosis, according to the American Heart Association. Despite receiving the same medications and medications, why do some people live longer than others? The researchers wanted to determine whether biomarkers of the nervous system could help explain the difference.
To date, no other biomarkers have specifically predicted the risk of death in patients with stable heart failure. The researchers analyzed the blood of 105 stable heart failure patients to find unique biomarkers to predict the likelihood of their death in the next few years.
The team found that neuropeptide Y levels were the clearest and most important death predictors. The scientists also compared patients’ neurotissue samples with those from healthy donors to determine whether neurons in people most likely to die from heart failure released higher levels of neuropeptides.
The team believes the findings could provide a way to distinguish between patients at high risk of stable heart failure and those with the same symptoms. This can help target patients who need more active and targeted treatment. The study also highlights the need for treatment for heart failure in the nervous system.